Current research on the diversity of hormone replacement therapy (HRT)-related effects does not necessarily focus on traditional issues, such as quality of life, cardiovascular disease, bone protection or cancer. Some studies highlight the effects of HRT on other organs and systems that are rarely addressed in the context of menopause medicine. Tint and colleagues  have investigated intra-ocular pressure (IOP) in young postmenopausal women who had no ophthalmic problems. Ninety-one ever-users of HRT (mean age 56 years) were compared with 172 never-users of postmenopausal hormones (mean age 61 years). The study showed that hormone users had a mean 1.4 mmHg lower IOP than that found in the non-users. Adjustment for age, time of measurement and concomitant therapy with beta-blockers did not change the results. There was no difference between women taking estrogen alone or a combination of estrogen and progestogen.
Department of Medicine T, Ichilov Hospital, Tel-Aviv, Israel
Tint NL, Alexander P, Tint KM, et al. Hormone therapy and intraocular pressure in nonglaucomatous eyes. Menopause 2009 Sep 16. Epub ahead of print.
Quigley HA, Braman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006;90:262-7.
Uncu G, Avci R, Uncu Y, et al. The effects of different hormone replacement therapy regimens on tear function, intraocular pressure and lens opacity. Gynecol Endocrinol 2006;22:501.
Pasquale LR, Rosner BA, Hankinson SE, et al. Attributes of female reproductive aging and their relation to primary open-angle glaucoma: a prospective study. J Glaucoma 2007; 16:598-605.
Defay R, Pinchinat S, Lumbroso S, et al. Relationships between hormonal status and cataract in French postmenopausal women: the POLA study. Ann Epidemiol 2003;13:638-44.
Freeman EE, Munoz B, Schein OD, et al. Hormone replacement therapy and lens opacities: the Salisbury Eye Evaluation project. Arch Ophthalmol 2001;119:1687-92.